Artificial Intelligence in Glioblastoma—Transforming Diagnosis and Treatment

Искусственный интеллект в лечении глиобластомы — трансформация диагностики и терапии
Alen Rončević, Nenad Koruga, Anamarija Soldo Koruga, Robert Rončević
2025-06-02

Artificial intelligenceGlioblastomaPersonalized treatmentRadiomicsTumor segmentation
Glioblastoma (GBM) is the most aggressive and common primary brain malignancy in adults, characterized by poor prognosis and treatment resistance. Despite advancements in treatment options, the median survival is roughly 15 months, underlining the need for novel and effective treatments. Artificial intelligence (AI) has emerged as a transformative technology in healthcare, offering outstanding capabilities in data analysis, pattern recognition, and helping in decision-making. This review explores the current and potential role of AI in GBM care, focusing on its applications in diagnosis, treatment planning, prognostication, and drug discovery. AI-based algorithms have demonstrated promising potential in enhancing diagnostics through imaging analysis, radiomics, and tumor segmentation. These technologies could enable non-invasive molecular profiling and early detection of GBM. In treatment planning, AI could improve approaches by optimizing surgical resection, radiotherapy regimen, and chemotherapy protocols. Furthermore, machine learning models can integrate multimodal data to develop personalized treatments. They can also enhance prognostication by predicting survival, recurrence, and treatment responses, helping clinicians to make more informed decisions. AI is also revolutionizing pharmacotherapy by identifying novel molecular targets and optimizing combination therapies. Despite notable progress, challenges persist. Limited data quality and quantity, algorithm interpretability, integration problems, and ethical considerations, remain significant challenges to clinical implementation. This review emphasizes the need for continued research and interdisciplinary collaboration to overcome many barriers and realize the transformative potential of AI in GBM care.
1
AI can facilitate drug discovery by identifying molecular targets and optimizing combination therapies, but clinical implementation is limited by data deficiencies, interpretability, integration, and ethical challenges.
2
AI may optimize surgical resection, radiotherapy, and chemotherapy while integrating multimodal data to support personalized treatment planning.
3
AI shows promise for improving GBM diagnosis through imaging analysis, radiomics, tumor segmentation, early detection, and non-invasive molecular profiling.
4
Glioblastoma remains highly lethal and treatment-resistant, with a median survival of roughly 15 months, motivating novel therapeutic strategies.
5
Machine-learning models can improve prognostication by predicting survival, recurrence, and treatment response, thereby supporting clinical decision-making.

Glioblastoma (GBM) care

Applications of artificial intelligence in GBM diagnosis, treatment planning, prognostication, and drug discovery

Publication Details
Publication Date
2025-06-02
Journal
Publisher
ISSN
Cited by
19
Access Type
Author Information
Authors
Alen Rončević
Nenad Koruga
Anamarija Soldo Koruga
Robert Rončević
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%